GlassScriptPhysician profile
Amy Wootten
NPI 1245200435
$3,270.91
in general payments reported to CMS, 2019-2025
25 companies · $446 in 2025
The $446 reported for 2025 was more than what 79% of Obstetrics & Gynecology (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Obstetrics & Gynecology (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $735 · 2022: $805 · 2023: $783 · 2024: $502 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,730.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,730.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $835.10 | 2021-2025 | Injectafer |
| Abbvie INC. | $411.69 | 2021-2023 | |
| Astellas Pharma US INC | $228.69 | 2022-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $224.14 | 2021-2025 | Slynd |
| Organon LLC | $210.85 | 2022-2025 | Nexplanon, Jada System |
| Novo Nordisk INC | $202.02 | 2023-2025 | Wegovy |
| Sumitomo Pharma America, INC. | $171.94 | 2023-2025 | Myfembree, Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $170.84 | 2021-2025 | |
| Myovant Sciences INC. | $147.35 | 2022 | |
| Mayne Pharma Commercial LLC | $128.46 | 2022-2025 | |
| Amgen INC. | $113.63 | 2021-2025 | Evenity, Prolia |
| Pfizer INC. | $112.98 | 2021-2024 | |
| Scynexis, INC. | $48.13 | 2022 | |
| Millicent US INC | $40.39 | 2025 | Femlyv, Intrarosa |
| Shield Therapeutics INC | $36.28 | 2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Therapeuticsmd, INC. | $28.50 | 2021 | |
| Ascend Therapeutics US, LLC | $24.49 | 2021 | |
| Lilly USA, LLC | $23.13 | 2023 | Zepbound |
| Evofem Biosciences, INC. | $19.39 | 2021 | |
| Convatec INC. | $16.84 | 2021 | |
| Merck Sharp & Dohme LLC | $16.67 | 2021 | |
| Urovant Sciences INC | $15.59 | 2022 | |
| Virtus Pharmaceuticals LLC | $15.36 | 2021 | |
| Renovia INC | $14.25 | 2021 | |
| Emd Serono, INC. | $14.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Wootten listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.